Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and PD-1 inhibitors in advanced HER-2 negative gastric cancer
NCT05721651Phase 2Recruiting
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial of fruquintinib in gastric cancer (GC). Started Apr 2023; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05721651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721651.